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 Cancer continues to rise steadily as a contributor to premature death in the 
developing world. Despite this, little is known about what aspects of national 
healthcare systems are associated with reduced mortality from cancer. Thus, we aimed 
to investigate the relationship between national healthcare system resources and 
cancer mortality.  The most recent estimates of cancer incidence and deaths were 
obtained for the 85 countries with reliable data. We defined cancer mortality to 
incidence ratio as deaths per year divided by incidence per year for a given cancer. 
Countries were categorized according to high (GDP>$15,000) or low-income 
(GDP<$15,000), and a multivariate linear regression model was used to determine the 
association between healthcare system indicators and cancer-specific mortality to 
survival ratio. Indicators studied included per capita gross domestic product (GDP), 
overall healthcare expenditure, health expenditure as a proportion of GDP, total 
external beam radiotherapy devices per capita (TEBD), physician density, and the year 
2000 World Health Organization (WHO) healthcare system rankings.  
 The overall cancer mortality to survival ratio in high income countries (47%) 
was significantly lower than that of low income countries (64%), with a p<0.0001. In 
high income countries, GDP, health expenditure and TEBD showed significant inverse 
correlations with overall cancer mortality to survival ratio, with health expenditure 
(overall and as a proportion of GDP)  showing the strongest relationship. For overall 
cancer, a $3,040 increase in GDP (p=0.004), a $379 increase in THE (p<0.0001), a 0.75% 
increase in THE per GDP (p<0.001) or an increase of 0.59 TEBD 100,000 population 
(p=0.027) were all associated with a 1% decrease in mortality to survival ratio.  In 
low income countries, only WHO score correlated with decreased overall cancer 
mortality to survival ratio (p=0.022).   
 Our analysis suggests that WHO healthcare score is associated with improved 
cancer outcomes in low income countries while absolute levels of financial resources 
and infrastructure play a more important role in high income countries. 
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Cancer is an important global problem, especially in the 
developing world. Greater than half of cancer cases worldwide arise in 
developing countries, and this proportion is expected to rise to 70% by 
2020 (1). As cancer incidence and mortality rates increase in the 
developing world on a yearly basis (2), the United Nations and WHO have 
placed greater emphasis on its treatment and prevention. September 2011 
marked the first ever High-Level Meeting of the United Nations on non-
communicable diseases, where researchers and policy makers united to 
forge new policies to tackle the growing worldwide epidemic of chronic 
disease.  This meeting will took place without essential data on the 
specific aspects of national healthcare systems that are associated 
with the variation of cancer mortality worldwide.   
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Given the cultural, socioeconomic, and environmental factors that 
can influence cancer outcomes, it is unclear whether and to what extent 
healthcare expenditure, infrastructure and organization are associated 
with cancer mortality rates.  Assessing overall health expenditure is 
perhaps the simplest method to measure a country’s commitment to 
healthcare.  Studies have shown weak but significant relationships 
between healthcare spending and improved cancer mortality in particular 
subsets of developed countries (3) (4), but this association is 
unexplored in the developing world.   
In addition to being associated with overall expenditure, cancer 
mortality may be affected by the specific aspects of healthcare 
infrastructure towards which spending is geared. Healthcare 
infrastructure can be measured in several ways.  In the developed 
world, the number of doctors per capita has been found to be associated 
with cancer mortality in some studies (3) but not in others (4). In 
addition to physician density, a useful measure of healthcare 
infrastructure is access to radiation therapy (5).  Radiation therapy 
is often underutilized in developing countries due to the up-front 
expense of required machines and facilities. In fact, 22 countries in 
Africa and Asia have no radiation therapy facilities at all, with many 
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more having only a fraction of the machines required by their 
populations (6). However, it is unclear whether access to radiation 
oncology facilities actually correlates with reduced cancer mortality 
worldwide. 
The overall functionality of a national healthcare system is 
another factor that could potentially affect cancer mortality. The year 
2000 World Health Organization (WHO) overall healthcare system rankings 
for example provided a systematically derived, quantifiable measure of 
healthcare system fairness and effectiveness. The rankings aimed to use 
available data from around the world to assess the effectiveness of 191 
countries in “Improving health, reducing health disparities, 
protecting households from impoverishment due to medical expenses, and 
providing responsive services that respect the dignity of patients,” 
(7). The ranking was a complex indicator that was based on the 
following factors: healthcare system responsiveness (based on overall 
patient satisfaction and the ability of a system to act promptly and 
effectively), the distribution of responsiveness (e.g. in rich vs. 
poor), overall level of health (measured by average disability adjusted 
life years), the distribution of health, and finally, the fairness of 
distribution of the financial burden of a system. Interestingly, they 
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ranked the USA, the nation spending the highest amount of money per 
capita on healthcare at the time, 37th (8). As a result of this 
surprising finding as well as debate within the scientific and 
political community regarding the methodology and utility of the 
rankings, little research has been done to see the effectiveness of the 
rankings in predicting national health outcomes. Indeed, no study to 
date has measured the association between these rankings and cancer 
mortality.  
 
Statement of Purpose 
The goal of this study was two-fold: to see the extent to which 
cancer mortality varied throughout the world and to identify the 
relation between healthcare system factors and cancer outcomes in both 
developed and developing countries. Broadly, we assessed three 
categories of variables with cancer mortality: overall monetary 
resources, healthcare system infrastructure, and the WHO’s overall 
healthcare system score. Due to the vast disparities in resources, 
healthcare systems and disease burdens in the developed vs. developing 
world, we hypothesized that factors affecting outcomes in low income 
countries would differ from those in high income countries. Thus we 
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assessed the healthcare system correlates of cancer mortality in each 
group separately.  
Methods 
Outcome Variable 
Age standardized cancer incidence and death rates were obtained 
from the International Agency for Research on Cancer’s Globocan 2008 
database, which included the most recent data from each country 
worldwide. While incidence data was available for a majority of 
countries, only 85 countries had recent (post 2005) non-estimated 
mortality data and were thus included for analysis. Of these 85 
countries, 41 were in Europe, 24 in the Americas, 17 in Asia, 2 in 
Oceania and only 1 in Africa. Data were stratified by cancer type, sex, 
and age, with groupings from 0-14 years, 15-39 years, 10 year groups 
until age 70, and 70+ years. As there are no standard international 
definitions of race and ethnicity, data were not stratified by race. 
There were 28 different cancer types reported, 26 in women and 24 in 
men. However, data from Kaposi Sarcoma was excluded from the evaluation 
as only two countries included this data, leading to a total of 27 
cancer types analyzed, 25 in women and 24 in men. Additionally, each 
country had a summary measure for all cancers excluding non-melanoma 
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skin cancer (overall cancer). The mortality to incidence ratio (M/I) 
was determined by dividing a given year’s mortality for a cancer by 
the cancer’s incidence in that year. While this is not an exact 
measure of survival, since being diagnosed with cancer in one year can 
lead to mortality in a different year, and incidence can change 
significantly from year to year, it is a simple and straightforward 
approximation that is useful for large datasets.  
 While a very broad range of countries from all continents are 
included, the poorest of poor countries, including all countries with 
GDPs of less than $1,690, were not included due to their lack proper 
and accurate cancer incidence and mortality databases. This list of 
excluded countries consists of all but one country in Africa, as well 
as many countries across Asia and Latin America.  
 
Table 1. Variables Used in Regression model 
Independent Variable Source Description 
WHO healthcare 
system score (overall 
and responsiveness) WHO World Health Report 2000  
The score was based on a system’s responsiveness to 
patients, the fairness of financial distribution, the overall 
national level of health, and the distribution of health 
Physician Density 
WHO Global Atlas of the Health 
Workforce 2008 Estimated number of physicians per 100,000 population  
Gross Domestic 
Product (GDP) 
World Development Indicators 
database, World Bank (2007) 
Estimated purchasing parity gross domestic product per 
capita in US$ 
Total Health 
Expenditure (THE) 
World Development Indicators 
database, World Bank (2007) 
Estimated total (government and private) health 
expenditure per capita in US$ 
THE per GDP 
World Development Indicators 
database, World Bank (2007) Estimated percent of THE as a proportion of GDP  
Radiation Therapy International Atomic Energy Agency’s total external beam radiotherapy devices per capita 
11 
Directory for Radiotherapy  2010 (TEBD) 
Control Variable Source  Description 
HIV rate CIA World Factbook 2003-2008 Estimated percent of population infected by HIV 
Rural population 
UN World Urbanization Prospects 
(2007) Estimated percent of  population that live in rural area 
Ethanol consumption WHO Core Health Indicators 2003 Estimated per capita liters of ethanol consumed 
Male smoking rate 
WHO Report on the Global Tobacco 
Epidemic 2007 Estimated percent of men who smoke tobacco regularly 
Female smoking rate 
WHO Report on the Global Tobacco 
Epidemic 2008 
Estimated percent of women who smoke tobacco 
regularly 
Male obesity rate WHO Global Database on BMI (2008) Estimated percent of men who have a BMI>30 
Female obesity rate WHO Global Database on BMI (2008) Estimated percent of women who have a BMI > 30 
Table 1 shows the independent variables and control variables that were used in the 







Table 2. Summary statistics by region for high and low income countries 

















Oceania    Overall  
Countries  12 18 5 5 2 2   44 
Mortality  55% 40% 50% 49% 49% 39%   47% 
Organization WHO Rank   61 16 55 29 37 37   36 
Financial 
Resources 
GDP  $21,043  $38,612  $31,212  $38,197  $42,393  $32,569    $32,418  
THE  $1,174  $4,451  $2,989  $1,552  $1,397  $3,388    $2,824  
THE per GDP  5.30% 11.40% 8.20% 4.60% 4.10% 10.40%   8.10% 
Healthcare 
Infrastructure 
TEBD  3.4 6 5.9 2 2.5 5.8   4.7 
Physician 
Density 



















Africa  Overall 
Countries  11 1 6 12 4 6 1 41 
Mortality  65% 61% 62% 59% 68% 73% 70% 64% 
Organization WHO Rank  76 61 77 72 99 121 175 92 
Financial 
Resources 




THE  $387  $564  $257  $406  $93  $126  $497  $269  
THE per GDP  4.10% 4.50% 3.40% 4.10% 2.00% 2.10% 4.70% 3.40% 
Healthcare 
Infrastructure 
TEBD  1.6 1 0.8 1.7 0.8 1.1 1.2 1.2 
Physician 
Density 
210 198 106 202 139 241 77 215 
Table 2 shows the mean for each variable used in the regression model (excluding 
controls) by region and income category. High income countries had a GDP > $15,000 
while low income countries’ were below $15,000. All variables varied widely by region 
and income category. Overall,  low income countries also had lower levels of resources 
and higher mortality than high income countries. Within high income countries, E. 
Europe had the worst mortality at 55% while Oceania and W. Europe had the best at 39-
40%. (p=0.006). Within low income countries, The Americas had lower mortalities than 
E. Europe and Asia . W. Asia, composed of former soviet states, had the highest 
mortality of any region at 73%. (Mortality = Overall cancer mortality, GDP = Gross 
Domestic Product per capita, WHO = World Health Organization, THE = total health 
expenditure per capita, TEBD = Total external beam radiation devices per 100,000 






 As previously mentioned, the markers chosen to correlate with 
cancer survival were World Health Organization (WHO) overall healthcare 
system score and system responsiveness score, physician density, per 
capita Gross Domestic Product (GDP), per capita total healthcare 
expenditure (THE), access to radiation oncology (measured by total 
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external beam devices (TEBD)  per capita) and THE per GDP. Table 1 
lists all indepndent variables as well as all control variables used in 
the study, with a listing of each variable's source. Table 2 shows the 
mean and ranges for the above variables overall and by region for both 
low and high income countries.  
WHO rankings 
 The first variable of interest was the year 2000 WHO overall 
healthcare system rankings (OHS), which ranked the USA, the nation 
spending the highest amount of money per capita on healthcare at the 
time, 37th (8). As previously mentioned, the ranking itself was derived 
from a score based on several variables: the system’s responsiveness 
to patients, the fairness of financial distribution, the overall 
national level of health, and the distribution of health. The 
responsiveness measure included two major components: respect for 
persons and client orientation. Fairness of financial distribution 
measured the relative out of pocket amount paid by the rich and poor. 
The overall national level of health was counted as the average 
disability adjusted life expectancy (DALE) of the nation. The 
distribution of health was concerned with the  
14 
variance of DALE around the mean. Our study took into account the 
overall healthcare system ranking as well as the specific measure of 
responsiveness to patients, as this measure was most likely to affect 
prompt diagnosis and treatment of malignancies. For statistical 
reasons, the absolute scores on which the ranks were based were used in 
the analysis.   
Physician Density 
 In addition to overall healthcare system scores, physician 
density plays a potentially important role in health outcomes. 
Theoretically, a greater number of physicians per capita would result 
in an increase of access of a population to physicians, and thus 
potentially earlier and more effective treatment of cancer. Previous 
studies on the subject have been equivocal. Or 2001 found that an 
increase in physicians per capita in 29 Organization for Economic 
Cooperation and Development (OECD) countries was associated with a 
significant reduction in potential years of life lost by cancer 
mortality in women, but not in men (3). Quaglia et al. 2005 on the 
other hand found that in 23 European countries, the density of 
healthcare employees did not correlate with improved cancer survival 
among the elderly (4). Thus the question still remains as to whether, 
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globally, there is an association between physician density and cancer 
survival. Our study used the measure of physicians per 100,000 
population as recorded in the WHO Global Atlas of the Health Workforce 
(9).  
GDP, THE & THE per GDP 
 Greater human resources are not the only part of a healthcare 
system that could provide improved outcomes. More financial resources 
on a national level theoretically allow for improved cancer prevention 
and treatment. Or 2001 showed a significant inverse relationship 
between GDP and years of life lost by cancer mortality in OECD 
countries (3). Quaglia et al. 2005 showed a significant positive 
correlation between both GDP and THE and cancer survival in European 
elderly (4). However, both studies only included a small cohort of 
countries and in the latter, a specific age population. This study 
aimed to see whether these trends hold on a more global scale. Per 
capita GDP and THE were based on 2007 World Bank estimates (10). 
Additionally, this study aimed to measure whether the importance of 
healthcare in a given society, as measured by the percent of GDP spent 
on THE (THE per GDP), correlated with cancer survival separate from 
either THE or GDP alone.  
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Radiation Therapy 
 With the question of cancer, not only are the number of 
physicians and the amount of spending on treatment potentially 
important to outcomes, but also where that spending goes. The three 
most common treatment modalities for any carcinoma are chemotherapy, 
surgery, and radiation therapy, with each type of carcinoma more 
responsive to one particular or a specific combination of treatments. 
Radiation therapy (RT) in particular has often been severely 
underutilized in developing countries, in large part due to the up-
front expense of required machines and facilities. As such, 22 
countries in Africa and Asia have no RT facilities at all, with many 
more having far fewer machines than required by their populations (6). 
In Africa for example, the supply of megavoltage radiation therapy 
machines was 18% of the estimated need (6). Despite large startup costs 
however, external beam radiation therapy in the long term is one of the 
most effective and cost effective cancer treatments (5). The speed and 
ease of treatment as well as the lack of need for expensive 
chemotherapeutic agents or dangerous surgeries make this a potentially 
excellent option for cancer treatment in developing countries. However, 
no study has been done to show whether access to radiation oncology 
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facilities actually correlates to improved health outcomes and improved 
cancer survival. Our study aimed to correlate survival with total 
external beam devices per capita (TEBD), both Linear Accelerators and 
Cobalt machines. TEBD data was obtained from the International Atomic 
Energy Agency’s Directory for Radiotherapy Centers, a detailed list of 
radiation therapy resources by country.  
Data Analysis 
 Multivariate regression modeling was performed using Stata 
version IC10 with the response variable of age standardized M/I. Three 
separate models were created for each cancer and predictor variable 
combination: one for males, one for females and one for both sexes 
combined. As this study aimed to assess predictors of overall cancer 
care, the summary measure of overall cancer M/I was the variable of 
greatest interest. However, analysis was done on all cancers 
individually as well to see whether any results found for overall 
cancers held for individual cancers. This step was performed to 
mitigate the potential confound caused by some countries having a 
higher incidence of more deadly cancers as a proportion of overall 
cancer incidence than others, thus artificially increasing their M/I. 
Each model included adjustments for the behavioral, demographic and 
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environmental risk factors listed in Table 1. Since GDP, THE and TEBD 
were collinear variables (pearson correlation coefficient>0.7 or < -
0.7), they were not included in each other’s models. However, 
physician density was included in all models as a control, as it was 
not collinear with the other predictor variables. See Table 3 for 
correlations between all predictor and control variables.  
 It was hypothesized that the relationship between predictor 
variables and M/I would be different in lower vs. higher income 
countries, thus the 85 countries were split roughly in half at the GDP 
point of $15,000 and the above regressions were repeated for the high 
and low GDP categories. Further breakdown into smaller GDP categories 
was not performed due to diminishing power. Correlation coefficients, 
regression coefficients and p-values were recorded for each regression 
equation. The amount of change needed in a given predictor variable to 
cause a 1% decrease in M/I was calculated by dividing 0.01 by the 
regression coefficient. 
19 





























































































































Score 0.68             
Physician Density 0.26 0.19            
GDP 0.68 0.75 0.24           
THE 0.63 0.71 0.36 0.83          
TEBD 0.63 0.70 0.42 0.70 0.87         
THE per GDP 0.63 0.66 0.40 0.66 0.93 0.87        
HIV Rate -0.30 -0.06 -0.25 -0.08 -0.10 -0.12 -0.08       
Rural population -0.50 -0.49 -0.24 -0.57 -0.45 -0.49 -0.44 0.04      
Ethanol 
Consumption 0.34 0.44 0.36 0.35 0.47 0.52 0.53 -0.03 -0.26     
Male Smoking -0.22 -0.26 0.26 -0.14 -0.24 -0.21 -0.28 -0.14 0.16 0.01    
Female Smoking 0.45 0.37 0.47 0.36 0.44 0.46 0.51 -0.15 -0.43 0.57 0.15   
Male Obesity 0.42 0.30 0.09 0.32 0.30 0.34 0.32 -0.08 -0.39 0.22 -0.15 0.45  
Female Smoking 0.02 -0.13 -0.22 -0.08 -0.07 -0.04 -0.04 0.18 -0.16 -0.03 -0.09 0.11 0.58 
Table 3 Shows the correlation between all variables, independent and control, used in 
the regression models. Correlations that are shown in bold (the vast majority) are 
significant, while correlations that are underlined meet the criteria for colinearity 
(r>=0.70) and were thus not included in each other's linear regression models. GDP, 
THE, THE per GDP, TEBD and WHO responsiveness score all showed significant colinearity 











Overall monetary resources, healthcare system infrastructure, 
healthcare system organization and overall cancer mortality varied 
significantly between high and low income countries, and from region to 
region, even within income categories (Table 2). Overall, low income 
countries also had lower levels of financial resources and 
infrastructure, as well as lower WHO healthcare scores and higher 
mortality than high income countries (p<0.0001 for all variables 
studied). Within high income countries, E. Europe had the worst 
mortality at 55% while Oceania and W. Europe had the best at 39-40%. 
(p=0.006). Within low income countries, the Americas had lower 
mortalities (59-62%) than E. Europe and Asia. W. Asia, composed of 
former soviet states, had the highest mortality of any region at 73%. 
Figure 1 shows a map representation of the overall cancer mortality to 
incidence ratios. Many of the highest mortality rates are found in 
former or current communist countries in Eastern Europe and Western 
Asia. In low income countries, mortality ranged from a low of 56% in 
Costa Rica to a high of 78% in Armenia with a median of 64% in 
Guatemala. In high income countries mortality ranged from a low of 38% 
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in Australia to a high of 73% in Greece with a median of 50% in Sweden. 
The United States and Luxembourg, the two largest healthcare spenders 
globally, were tied for second at a 39% overall mortality rate. A list 
of all countries studied ranked by overall cancer mortality to 
incidence ratios is shown in Table 4. 
 Several variables correlated significantly with M/I in the 
regression models. The results for overall cancer are outlined in Table 
5 and each variable is addressed individually below. It is interesting 
to note that for every variable that proved significant, the 
correlation was stronger (lower p-value) in men than in women, showing 
that all variables had greater predictive value in the former.  
WHO Scores 
 For low income countries, only WHO overall score correlated 
significantly with overall cancer M/I, and only in the combined 
statistic for both sexes, but not in each sex individually. A 1% 
decrease in overall cancer mortality to incidence ratio correlated with 
a 7.0% increase in WHO overall healthcare system score (p=0.022). In 
high income countries, WHO overall score correlated with improved 
outcome in stomach, testicular and head and neck cancers only, but not 
overall cancer. WHO responsiveness score on the other hand, correlated 
22 
poorly with M/I in low income countries. In high income countries, 
responsiveness score did correlate significantly with overall cancer 
rate in all three sex categories. 
23 





















Figure 1 shows a color coded map of age-adjusted mortality to incidence ratios (M/I) 
for all cancers. Lighter colors correspond with lower mortality rates. As seen 
numerically in Table 2, Western Europe, Oceania and North America have the lowest M/I. 
In low income countries, Central and South America have lower M/I  than much of 
Eastern Europe and Asia.  Many of the highest M/I are found in former or currently 


















Table 4. Ranking of Countries by Overall Cancer Mortality per Incidence 
Rank Country M/I Rank Country Mortality Rank Country M/I 
1 Australia 38.26% 30 Costa Rica 55.54% 59 Guatemala 64.41% 
2 Luxembourg 38.61% 31 Suriname 55.58% 60 Hungary 64.61% 
3 United States 39.37% 32 Japan 55.64% 61 El Salvador 64.95% 
4 New Zealand 40.55% 33 Portugal 56.31% 62 Belize 65.07% 
5 Ireland 40.61% 34 Brunei 56.69% 63 Moldova 65.25% 
6 Israel 40.79% 35 Venezuela 57.51% 64 Trinidad and Tobego 65.27% 
7 Republic of Korea 40.87% 36 Argentina 57.75% 65 Albania 65.69% 
8 Iceland 42.48% 37 Bahamas 57.97% 66 Belarus 65.82% 
9 Finland 42.78% 38 Colombia 58.14% 67 Ecuador 65.88% 
10 Norway 42.97% 39 Bulgaria 58.41% 68 Poland 65.91% 
11 Canada 43.64% 40 Slovenia 58.62% 69 Romania 66.12% 
12 France 43.78% 41 Lithuania 59.23% 70 Russian Fed 66.38% 
13 Kuwait 44.19% 42 Brazil 59.25% 71 Mauritius 66.57% 
14 Germany 44.22% 43 Uruguay 59.31% 72 Cuba 67.34% 
15 Switzerland 45.11% 44 Nicaragua 59.85% 73 South Africa 68.93% 
16 Belgium 46.82% 45 Paraguay 60.09% 74 China 69.26% 
17 Singapore 47.24% 46 Barbados 60.14% 75 Turkmenistan 69.93% 
18 Cyprus 47.25% 47 FYR Macedonia 60.24% 76 Kyrgyzstan 70.21% 
19 Italy 48.71% 48 Croatia 60.42% 77 Uzbekistan 70.40% 
20 Denmark 48.89% 49 Dominican Republic 60.88% 78 Serbia 71.30% 
21 Sweden 49.67% 50 Mexico 60.94% 79 Georgia 71.37% 
22 The Netherlands 49.74% 51 Ukraine 61.14% 80 Mongolia 72.76% 
23 Czech Republic 50.95% 52 Chile 61.39% 81 Tajikistan 72.87% 
24 United Kingdom 51.42% 53 Thailand 62.53% 82 Greece 73.41% 
25 Chinese Taipei 52.65% 54 Philippines 62.55% 83 Kazakhstan 74.00% 
26 Spain 52.94% 55 Latvia 62.62% 84 Azerbaijan 77.20% 
27 Malta 54.64% 56 Peru 63.18% 85 Armenia 78.17% 
28 Austria 55.26% 57 Estonia 64.09%    
29 Slovakia 55.46% 58 Panama 64.40%    
Table 4 lists all countries included in the study ranked by Mortality to Incidence 
Ratio (M/I) as a percentage. Countries in red are high income as decided by the study 
parameter of GDP>$15,000 while countries in green are low income (GDP<$15,000). In 





Table 5. Significantly Correlating Variables by Sex and Income Category 











































WHO Overall Score - - - 7.0% (3.8%, 44.4%) 0.022 
WHO Responsiveness Score 2.0% (1.1%, 7.5%) 0.009 - - - 
GDP $3,040 ($1828, $9091) 0.004 - - - 
THE $379 ($248, $800) <0.0001 - - - 
THE/GDP 0.75% (0.46%, 1.95%) <0.0001 - - - 
TEBD per 100,000 0.59 (0.31, 4.93) 0.027 - - - 
TEBD/THE -0.031% 
(-0.112%, -
0.018%) 0.008 - - - 









WHO Overall Score - - - - - - 
WHO Responsiveness Score 2.8% (1.6%, 20.1%) 0.024 - - - 
GDP $3,745 ($2128, $15649) 0.012 - - - 
THE $575 ($333, $2105) 0.008 - - - 
THE/GDP 1.30% (0.68%, 13.76%) 0.031 - - - 
TEBD per 100,000 - - - - - - 
TEBD/THE -0.037% 
(-0.15%, -
0.021%) 0.011 - - - 






WHO Overall Score - - - - - - 
WHO Responsiveness Score 1.7% (1.0%, 5.3%) 0.005 - - - 
GDP $2,667 ($1642, $7092) 0.002 - - - 
THE $358 ($229, $820) 0.001 - - - 
THE/GDP 0.76% (0.45%, 2.53%) 0.006 - - - 
TEBD per 100,000 0.54 (0.28, 6.4) 0.033 - - - 
 TEBD/THE -0.031% 
(-0.118%, -
0.018%) 0.009    
 Physicians per 100,000     -42 (-91, -27) 0.001 
     
 
   
Table 5 shows significant correlates of overall cancer mortality to incidence ratio 
(M/I), as well as the increase in each variable needed to cause a 1% decrease in 
cancer mortality (1% change in M/I). For example, in high income countries, a $3,040 
increase in GDP per capita is associated with a 1% decrease in overall cancer 
mortality (p=0.004). While GDP, THE, THE per GDP, WHO responsiveness score and TEBD 
all showed significant inverse correlations with mortality in high income countries, 
THE and THE per GDP showed the strongest correlations (highest R and lowest p-value). 
In low income countries, only WHO overall score correlated with decreased overall 
cancer mortality while physician density paradoxically correlated with increased 
mortality. (GDP = Gross Domestic Product per capita, WHO = World Health Organization, 
26 
THE = total health expenditure per capita, TEBD = Total external beam radiation 
devices per 100,000 population, Physician Density = Physicians per 100,000 population) 
A 1% decrease in overall cancer M/I correlated to a 2.0% increase in 
WHO responsiveness score (p=0.009). Specifically, improvement in WHO 
responsiveness score was associated with significant decrease in M/I of 
stomach, kidney, colon, breast, cervix, CNS, testis, non-Hogdkin 
lymphoma, and head and neck cancers. 
GDP, THE and THE per GDP: 
 In low income countries, GDP, THE and THE per GDP did not 
correlate with overall cancer M/I in any sex category. Interestingly, 
M/I correlated positively with GDP for Lung, pancreas, stomach, and 
cervical cancer, meaning that as GDP increased in low income countries, 
survival decreased for these cancers. Only Hodgkin lymphoma had the 
expected inverse correlation with GDP.  No individual cancer showed any 
significant correlation with THE, and only the M/I of gallbladder 
cancer in men showed a significant inverse correlation with THE.  
 In high income countries, GDP, THE and THE per GDP all correlated 
significantly with overall cancer M/I in all three sex categories. In 
both sexes combined, a 1% decrease in overall cancer mortality 
correlated with an increase of $3,040 for GDP (p=0.004), $379 for THE 
(p<0.0001) and 0.75% of GDP for THE per GDP (p<0.0001). The following 
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cancers had a significant inverse correlation with all three variables: 
colorectal, breast, cervix, liver, CNS, kidney, stomach, testis, liver 
and head and neck. Non-Hodgkin lymphoma, lung and bladder  cancer 
correlated with both THE and GDP but not THE per GDP, while a few 
cancers correlated only with each individual variable. For overall 
cancers, M/I correlated most significantly with THE, as evidenced by 
the fact that its p value was lowest in all three sex categories (See 
Table 5). Two of the three countries with the absolute lowest overall 
cancer M/I’s, Luxembourg (0.386) and the United States(0.394), also 
had the highest THEs at $7439 and $7285 respectively. 
TEBD and Physician Density 
 In low income countries, TEBD did not correlate significantly 
with overall cancer M/I. Physician density, surprisingly, showed a 
positive correlation in all three sex categories (p= 0.009), with an 
increase of 39 physicians per 100,000 leading to a 1% increase in 
overall cancer M/I for both sexes. Specifically, colorectal, Hodgkin 
lymphoma, head and neck, and ovarian cancer M/Is correlated 
significantly with physician density. 
In high income countries, TEBD showed a significant inverse correlation 
with the M/I of overall cancers in men alone and both sexes combined 
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(0.027), but not in women alone. For overall cancer, a 1% decrease in 
M/I correlated with an increase of 0.59 external beam devices per 
100,000 population. M/I of colorectal, CNS, stomach, liver, breast, 
lung, cervix, head and neck cancers correlated significantly with TEBD.  
Physician density on the other hand, correlated poorly with M/I in 
these countries. 
Discussion: 
Cancer mortality varied widely throughout the developed and 
developing world. Quantifiable measures of overall monetary resources, 
healthcare infrastructure, and healthcare system organization appeared 
to impact cancer mortality in different ways in higher vs. lower income 
countries. While financial resources and infrastructure showed 
significant correlations with overall cancer mortality in high income 
countries, low income countries showed correlations with none of these 
factors. This was not simply due to lack of power, as some measures of 
resources showed paradoxical weak (not statistically significant) 
positive correlations with mortality. For low income countries, WHO 
overall healthcare system score was the only variable strongly 
associated with improvement in overall cancer mortality. This score 
took into account not only general population health but also a 
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system’s responsiveness to its patients and the equitable distribution 
of health and healthcare within a country. This finding suggests that 
for poor countries, increased healthcare expenditure may not 
significantly improve national cancer mortality in the presence of 
unequal distribution of healthcare resources.  Indeed there may be a 
minimum threshold beyond which an increase in healthcare expenditure 
and infrastructure is associated with improved cancer mortality.   
While WHO overall healthcare score was associated with improved 
cancer mortality in low income countries, no association was seen in 
high income countries.  The differential results in high vs. low income 
countries at the same time validate and undermine the utility of the 
WHO score in assessing a healthcare system’s ability to treat cancer 
effectively. The score’s relationship with the end-measure of 
mortality depends on context. As noted previously, a large part of the 
WHO healthcare system score is based on the equality of health 
resources distribution. In the setting of relatively low national 
resources, equality is very important – to spread out the limited 
healthcare expenditure available so that everyone has access to the 
most basic cancer screening and treatment.  In high income countries, 
because the most modern cancer treatment is so expensive (11), it may 
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be difficult to provide the most technologically advanced treatments to 
every single person that needs it.  More equitable high income 
nationalized systems may choose not to offer the most advanced 
treatments at all in order to limit costs and focus more on less 
expensive diseases. Thus, high income countries which offer the most 
advanced but expensive treatments to only a portion of the population, 
may have an edge in overall cure rates compared to their more equitable 
counterparts. 
Among the variables chosen, the WHO score had particular 
drawbacks but also particular promise. A small portion of the score was 
based on national levels of health measured by disability adjusted life 
years lost to disease. As our dependent variable was cancer mortality, 
and higher cancer mortality within a country would potentially lead to 
poorer national levels of health, it was hypothesized that there could 
be the potential of testing a circular relationship. However, as this 
relationship was only a small part of the overall relationship being 
tested, it was decided to include the WHO score as a variable. The 
complexity of the score’s algorithm, a source of much debate in the 
scientific community, was another reason the score was chosen. The 
score attempted the herculean task of quantifiably measuring the 
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overall fairness and effectiveness of a healthcare system. Thus, in our 
model it served as a gestalt measure of a healthcare system’s 
performance and organization to counterbalance the very specific 
measures of resources and infrastructure. While the merits and pitfalls 
of this score could be debated endlessly, the significant correlation 
between the score and overall cancer mortality in low income countries 
provides partial evidence in support of the score’s utility. At the 
very least, this result should fuel further research on the 
relationship between the score and health outcomes. 
 The first question that arises from the above results is why do 
WHO overall healthcare system scores fail to predict cancer outcomes in 
high income countries? Cancer treatment is a resource intensive 
process. In the United States for example, the average cost of initial 
treatment for colorectal and lung cancer, two of the most common 
cancers worldwide, are between $60,000 and $75,000 per person (11). 
Expensive chemotherapeutic agents, surgeries and radiation treatments 
are required, often for only a small chance of improvement or cure. 
However, without these expensive and aggressive treatments, the chances 
of improvement or cure would be even less. A large part of the WHO 
overall healthcare system score is based on the equity of health 
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resources distribution. In more equitable healthcare systems, which 
would gain a higher rank, there is more of a managed care approach; as 
such, expensive treatments with small chances of causing an improvement 
in survival are often not undertaken for financial reasons (12, 13). 
Thus, in high income countries, an improvement in WHO overall 
healthcare system rank would not necessarily lead to improved cancer 
survival, as a managed care or nationalized healthcare approach with 
more equitable distribution of resources would potentially limit the 
aggressiveness of treatment of patients with poorer prognoses and 
diseases that have very expensive treatments. On the contrary, in a 
less equitable system that has components which are fee for service, 
there is greater physician incentive for more costly and aggressive 
treatments, and less pressure to control costs (14). This more 
aggressive care could potentially result in improved cancer survival on 
the whole, albeit at high costs. Thus it is also not surprising that 
THE correlates so significantly with survival in high income countries.  
In low income countries on the other hand, greater equity in 
access to healthcare and cost distribution means that at least the 
majority of the population have access to the most inexpensive cancer 
treatments. This explains why WHO overall healthcare rank correlates 
33 
well with survival in low income countries. However, another question 
that arises is why do healthcare system resources such as THE or TEBD 
fail to predict outcomes in low income countries? One possible answer 
is that the variation in these indicators is too small in low income 
countries to show any predictive value. For example, the range of THE 
in low income countries is $634 ($29 in Tajikistan to $663 in 
Argentina), while it is $6,732 ($716 in Poland to $7439 in Luxembourg) 
in high income countries. Similar disparities in range exist for GDP, 
TEBD and THE per GPD.  This finding suggests one of two things: that 
the variation in resources was too small in low income countries to 
show a statistically significant correlation with survival given the 
relatively small sample size, or, that there may be a threshold before 
which resources cannot cause an improvement in cancer survival. Further 
research is necessary to determine whether this threshold exists and 
what values of GDP, THE, THE per GDP or TEBD prove to be cutoff points 
before which significant improvement in cancer outcomes are not seen. 
While GDP, overall healthcare expenditure, expenditure as a 
proportion of GDP, and access to radiation oncology were all 
significant inverse correlates of mortality in high income countries, 
the overall data suggests that overall healthcare expenditure showed 
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the strongest correlation. Thus, in countries with a GDP>$15,000, 
healthcare spending truly does make a difference in fighting cancer, 
both as an absolute value, and as a proportion of a nation’s budget. 
The most significant difference is seen in the most treatment and 
screening sensitive cancers, namely breast and colorectal cancer. 
Access to radiation therapy (as measured by total external beam devices 
per capita) also has the strongest association with both of these 
cancers, where adjuvant radiation therapy is often the standard of 
care.  
Limiting our study was the lack of data on the poorest of all 
countries, particularly those in Africa. African countries have a per 
capita GDP on average less than half of the next most resource limited 
continent, Asia.  However, the burden of cancer is huge in Africa. For 
example, the risk of dying from cancer among African women is actually 
double that of developed countries (15). Thus, future research 
attempting to analyze correlates of cancer mortality in the poorest of 
poor countries is an absolute necessity. Another limitation was the 
potential impact of unmeasured variables on cancer outcomes. For 
example, expenditure on social welfare has been shown to be an 
independent correlate of general health outcomes in developed 
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countries, even surpassing healthcare expenditure itself in some 
countries (7).  
 One very surprising result was that physician density not only 
failed to correlate with survival in high income countries, but it also 
had a significant inverse correlation with survival (direct correlation 
with M/I) in low income countries. This result ties in perfectly with 
geography and politics. Of the 18 low income countries with the highest 
physician density, 17 are current or former communist countries, 
including Cuba, former members of the Soviet Union and the Eastern 
Bloc. On the other hand, the vast majority of low income countries with 
the lowest physician densities are Latin American countries with no 
strong history of communism. This trend can easily be seen by looking 
at the color difference between Soviet and Eastern Bloc countries vs. 
Central and South American ones in Figure 1. It is understandable that 
countries with communist backgrounds employ more socialized healthcare 
systems with more centralized systems of physician training and higher 
physician densities (16). However, why do these countries also have 
poorer survival rates? This difference cannot fully be explained by 
economic factors as several of the countries in Latin America for 
example have equal or lower GDPs and THEs to those in Eastern Europe, 
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but better survival rates. One possible explanation ties this result 
back to the previous comparison of managed care vs. fee for service 
based healthcare systems. Current or former communist countries are 
more likely to have a population-based approach to healthcare rather 
than an individual based approach, thus putting less emphasis on 
treating individuals with costly diseases than in treating cheaper 
diseases that are deemed treatment worthy by the state (17). 
 While GDP, THE, THE per GDP, TEBD and WHO responsiveness score 
were all significant positive correlates of survival in high income 
countries, the overall data suggests that THE is the strongest 
predictor. Due to the collinearity of the aforementioned variables, 
parsing out the importance of one over the other posed a significant 
challenge. The first and simplest way of comparing effects was to 
compare the p-value of each correlation. THE and THE per GDP had the 
lowest p-values at p<0.0001 in the both sexes category, while THE alone 
won the battle in each sex individually. Since THE per GDP is 
combination of THE and the inverse of GDP, it is a useful variable in 
assessing the relative strength of the two. Thus, the fact that THE per 
GDP showed a significant inverse correlation with M/I supports the 
hypothesis that THE has greater predictive value than GDP. It is also 
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quite possible, that because all of the above variables are collinear, 
either a common underlying variable or THE alone is accountable for the 
correlations seen. 
 Considering the cost of modern cancer care, the apparent effect 
of THE on survival is not at all surprising. Any potential effect of 
THE on M/I will have to come through one of two routes: improved cancer 
screening leading to detection at earlier stages, or, improved 
treatment after detection. If the former were the case, the most common 
cancers for which there are widely established screening mechanisms 
(such as colon, breast and prostate cancer) and effective early stage 
treatment would be most affected by rising THE. If the latter were the 
case, THE’s effects would be most pronounced in the most costly 
cancers to treat. Using recently published data from Mariotto et al. 
2011 regarding the cost of treatment by cancer in the United States, as 
well as our global incidence and mortality data, we wished to see 
whether THE was more likely to correlate with the M/I for higher 
costing and more prevalent cancers (11). However, no relationship was 
found in either case. While it was true that the M/I of costly cancers 
(such as CNS cancers) and common treatable cancers (such as colorectal 
and breast cancer) correlated significantly with THE, so did several 
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cancers that were relatively uncommon and inexpensive to treat. Thus 
the mechanism of any potential effect of THE on M/I remains uncertain. 
 In high income countries, every single significantly correlating 
variable (THE, GDP, THE/GDP, WHO responsiveness score, TEBD) showed a 
much stronger correlation with M/I in men than women (as evidenced by a 
lower p-value). This result held both for overall cancers and head to 
head comparisons of individual cancers. Such a finding would lead us to 
believe that improvements in healthcare system resources have a 
potentially stronger effect on men than women. But why would this be? 
Traditionally, women are seen as the sex that takes better care of 
their health and visits the doctor more frequently. Several studies 
have found that women have higher overall utilization of the healthcare 
system in the United States (18). So what exactly is it about cancer 
care that’s different in men than women? A British study found that in 
a cohort of 5462 community members, men were significantly more likely 
to take part in colon cancer screenings than women (19). A Japanese 
study found that women with stomach cancer (the most common cancer in 
the country) presented at a significantly later stage than men, and 
consequently had decreased survival rates (20). Thus perhaps when it 
comes to certain common cancers, women are for some reason less likely 
39 
to undergo screening, and more likely to present at later stages. This 
hypothesis would explain why improvement in healthcare systems and 
healthcare resources would have less of an effect on women than men.  
 In this paper, we have shown the importance of financial 
resources in predicting survival in high income countries compared to 
the primacy of healthcare system organization as determined by the WHO 
in low income countries.  While we have shown differences in the 
strength of effect of each variable, it is difficult to be certain of 
how direct the effect is. As this is a retrospective correlational 
study, the potential covert effect of one or several unknown variables 
that dictates the above healthcare system indicators cannot be 
excluded. Additionally, despite efforts to separate the effects of each 
variable, a more complex interdependent relationship between all of the 
healthcare system indicators in predicting M/I is likely. This point is 
clearly evidenced in the above discussion regarding physician density 
in former Communist countries. It is also important to note the 
geographic limitations of this study. As the study was limited to 
countries with robust data collection mechanisms, the vast majority of 
Africa and a significant portion of Asia were excluded. Thus, the 
results cannot be extrapolated to these areas. That being said, the 
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range of countries sampled was quite broad, with many countries having 
a THE that was greater than the entire GDP of their counterpart. The 
United States’ THE of 7285 for example was four times the GDP of 
Turkmenistan. 
 This report opens up more questions than it answers, especially 
in regards to finding the optimal healthcare system for treating 
cancer. On some levels, our study provides justification for the 
seemingly astronomical costs of medical care in many developed 
countries such as the United States. The higher costs actually produce 
real improvements in cancer survival. Additionally, despite many 
concerns related to healthcare access and equitability in more complex 
fee for service systems such as that of the United States, such 
countries often outperform more equitable systems in cancer survival. 
However, as this was a correlational study, further analyses are 
required. Specifically, studies are necessary to find additional hidden 
factors that may predict cancer survival and parse out the extent and 
mechanism of influence of both known and unknown factors.  
Conclusion 
This paper serves as the first analysis to explore the 
relationship between healthcare system indicators and cancer outcomes 
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across the globe. Cancer mortality varied widely throughout high and 
low income countries. While overall financial resources and healthcare 
infrastructure were strongly associated with cancer mortality in high 
income countries, the World health Organization’s healthcare system 
score, a measure of healthcare system performance, organization and 
equality, was the only correlate of mortality in low income countries.  
This suggests a greater importance of healthcare system structure and 
equality in lower income countries vs. absolute levels of resources in 
higher income countries.  
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